Berapakah harga Boundless Bio, Inc. (BOLD)

Harga Boundless Bio, Inc. (BOLD) adalah $3.00

Apakah topi pasaran Boundless Bio, Inc. (BOLD)

Cap pasaran Boundless Bio, Inc. (BOLD) adalah $67.31M

Boundless Bio, Inc. (BOLD) Hasil Dividen

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

Tahun	Hasil Dividen	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil Dividen

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil Dividen	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH

Syarikat

Hasil Dividen

Negara

Vertex Pharmaceuticals Incorporated

VRTX.US

0.00%

Argenx SE

ARGX.US

0.00%

Moderna, Inc.

MRNA.US

0.00%

CSL Limited

CSL.AX

3.12%

Lonza Group AG

LONN.SW

0.00%

Boundless Bio, Inc.

BOLD

Kategori